Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Find clear guidance on which blue chip coin to start with, including risk notes and a simple starter approach for newcomers.
22,023 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
GitLab posted its Q4 FY2026 results after the bell, showing revenue and earnings that set the stage for 2027. Stocks ...
Stellantis faces a tougher profitability and cash-flow comparison with its peers. But for patient investors, the long...
Bitcoin climbs toward $72,000 as spot ETF inflows continue into a second session, despite rising geopolitical risk in...
Adobe has pulled back about 40% from its peak, but new AI-driven products and expanding ARR are reinvigorating the bu...
A national study shows property taxes, insurance account now comprise about 21% of a typical mortgage payment, intens...
SpaceX, Rocket Lab, and AST SpaceMobile retreat as a China rocket milestone and an oil price spike pressure space-sto...
Take-Two Interactive faces a mix of franchise strength and execution risks. This article breaks down whether the stoc...
Google Gemini AI projects a sharp, liquidity-driven Bitcoin rally to as high as $150,000 by the end of 2026, undersco...
Orion Group stock dropped experienced intraday swings, illustrating how earnings, guidance, and market sentiment can ...
The June CPI report showed a 0.4% month-over-month decline, boosting Bitcoin and other risk assets. BTC briefly touch...
March 2026 brings choppy markets and rising demand for fast, reliable screeners. This piece ranks the best stock scre...